Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study

David Olmos, Daniel Brewer, Jeremy Clark, Daniel C Danila, Chris Parker, Gerhardt Attard, Martin Fleisher, Alison Hm Reid, Elena Castro, Shahneen K Sandhu, Lorraine Barwell, Nikhil Babu Oommen, Suzanne Carreira, Charles G Drake, Robert Jones, Colin S Cooper, Howard I Scher, Johann S de Bono

Research output: Contribution to journalArticlepeer-review

93 Citations (Scopus)


Biomarkers are urgently needed to dissect the heterogeneity of prostate cancer between patients to improve treatment and accelerate drug development. We analysed blood mRNA expression arrays to identify patients with metastatic castration-resistant prostate cancer with poorer outcome.
Original languageEnglish
Pages (from-to)1114-24
Number of pages11
JournalThe Lancet Oncology
Issue number11
Publication statusPublished - Nov 2012


  • Aged
  • Aged 80 and over
  • Castration
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Inflammation
  • Male
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Prognosis
  • Prospective Studies
  • Prostatic Neoplasms
  • Messenger RNA
  • Survival Analysis
  • Tumor Markers (Biological)

Cite this